Suggested Readings

 

 

Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease.

Arranz J, Zhu N, Rubio-Guerra S, et al. Alz Res Therapy. 2024;16(1)139.

Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with anti-amyloid beta therapy.

Barakos J, Purcell D, Suhy J, et al. J Prev Alzheimers Dis. 2022;9(2):211-220.

Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke.

Reish NJ, Jamshidi P, Stamm B, et al. N Engl J Med. 2023;388(5):478-479.

Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.

Sims JR, Zimmer JA, Evans CD, et al. JAMA. 2023;330(6):512-527.

Lecanemab in early Alzheimer’s disease.

van Dyck CH, Swanson CJ, Aisen P, et al. N Engl J Med. 2023;388(1):9-21.

Clinical impact of microbleeds in patients with Alzheimer’s disease.

Vázquez-Justes D, Aguirregoicoa I, Fernandez L, et al. BMC Geriatrics. 2022;22(1):774.

Linked Resources

Downloadable Handouts

Neurology Checklist for Antiamyloid Monoclonal Antibodies

Infusion Center Checklist for Antiamyloid Monoclonal Antibodies for Alzheimer's Disease

Radiology Checklist for Antiamyloid Monoclonal Antibodies

Emergency Department Checklist for Antiamyloid Monoclonal Antibodies for Alzheimer's Disease

A Clinician's Guide to Using for Antiamyloid Monoclonal Antibodies for Alzheimer's Disease

What Do Patients and Caregivers Need to Know About for Antiamyloid Monoclonal Antibodies for Alzheimer's Disease?

Clinical Practice Guidelines

Lecanemab: appropriate use recommendations.

Cummings J, Apostolova L, Rabinovici GD, et al. J Prev Alzheimers Dis. 2023;10(3):362-377.

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer’s Association Workgroup

Jack CR, Jr., Andrews JS, Beach TG, et al. Alzheimers Dement. 2024;20(8):5143-5169.

International Nuclear Medicine Consensus on the clinical use of amyloid positron emission tomography in Alzheimer’s disease.

Tian M, Zuo C, Civelek AC, et al. Phenomics. 2023;3(4):375-389.

Clinician, Patient, and Caregiver Resources

AD8 dementia screening interview

Alzheimer’s Association

The Alzheimer’s Questionnaire

Monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease CED study registry

Center for Medicare and Medicaid Services.

LEQEMBI® (lecanemab) prescribing information.

US Food and Drug Administration (FDA).

KISUNLA (donanemab) prescribing information.

FDA.

Mini-Mental State Exam (MMSE) Alzheimer’s / dementia test: administration, accuracy and scoring

Montreal Cognitive Assessment Test (MoCA) for dementia & Alzheimer’s 

Standardized Mini-Cog© Instrument

Related events
AUG
15
2025
BRIDGE AD 2025
1.00 CME

Neurology Center of New England, PC

Workshop 2 - Overcoming Hurdles to Antiamyloid mAb Clinic Protocol Development

Time: 8:00 AM-9:00 AM ET
Venue: Neurology Center of New England, PC
Location: Foxboro, MA
Faculty: David C. Weisman, MD
Register Now
JUL
18
2025
BRIDGE AD 2025
1.00 CME

Neurology Center of New England, PC

Workshop 1 - Laying the Foundation for Administering Antiamyloid mAbs for Patients With Early AD

Time: 8:00 AM-9:00 AM ET
Venue: Neurology Center of New England, PC
Location: Foxboro, MA
Faculty: David C. Weisman, MD
Register Now
OCT
10
2025
BRIDGE AD 2025
1.00 CME

Penn State Neuroscience Institute

Workshop 1 - Laying the Foundation for Administering Antiamyloid mAbs for Patients With Early AD

Time: 2:00 PM-3:00 PM ET
Venue: Penn State Neuroscience Institute
Location: Hershey, PA
Faculty: David C. Weisman, MD
Register Now
NOV
21
2025
BRIDGE AD 2025
1.00 CME

Penn State Neuroscience Institute

Workshop 2 - Overcoming Hurdles to Antiamyloid mAb Clinic Protocol Development

Time: 2:00 PM-3:00 PM ET
Venue: Penn State Neuroscience Institute
Location: Hershey, PA
Faculty: David C. Weisman, MD
Register Now